Changes include increased transparency, delayed DMEPOS payment reductions, changed reimbursement for infusion drugs, changed hospital policies and more.

On December 13, 2016, President Obama signed into law the 21st Century Cures Act (the Act) with strong bipartisan support. The Act includes several Medicare reforms and updates to existing Medicare policies affecting pharmaceutical and device manufacturers as well as healthcare providers and suppliers. Overall, the Act represents an effort to achieve Medicare and Medicaid program savings while improving access to new technologies and healthcare services for Medicare beneficiaries and Medicaid recipients. This article provides a summary of the key provisions impacting pharmaceutical and medical device manufacturers; durable medical equipment (DME) prosthetics, orthotics and supplies (DMEPOS) suppliers; providers of infusion drugs furnished through DME; home infusion therapy services; and hospitals.